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Abstract
Anthelmintic resistance is a major problem in livestock farming, especially of small ruminants, but our understanding of it
has been limited by the difficulty in carrying out functional genetic studies on parasitic nematodes. An important nematode
infecting sheep and goats is Haemonchus contortus; in many parts of the world this species is resistant to almost all the
currently available drugs, including ivermectin. It is extremely polymorphic and to date it has proved impossible to relate
any sequence polymorphisms to its ivermectin resistance status. Expression of candidate drug-resistance genes in
Caenorhabditis elegans could provide a convenient means to study the effects of polymorphisms found in resistant
parasites, but may be complicated by differences between the gene families of target and model organisms. We tested this
using the glutamate-gated chloride channel (GluCl) gene family, which forms the ivermectin drug target and are candidate
resistance genes. We expressed GluCl subunits from C. elegans and H. contortus in a highly resistant triple mutant C. elegans
strain (DA1316) under the control of the avr-14 promoter; expression of GFP behind this promoter recapitulated the pattern
previously reported for avr-14. Expression of ivermectin-sensitive subunits from both species restored drug sensitivity to
transgenic worms, though some quantitative differences were noted between lines. Expression of an ivermectin-insensitive
subunit, Hco-GLC-2, had no effect on drug sensitivity. Expression of a previously uncharacterised parasite-specific subunit,
Hco-GLC-6, caused the transgenic worms to become ivermectin sensitive, suggesting that this subunit also encodes a GluCl
that responds to the drug. These results demonstrate that both orthologous and paralogous subunits from C. elegans and H.
contortus are able to rescue the ivermectin sensitivity of mutant C. elegans, though some quantitative differences were
observed between transgenic lines in some assays. C. elegans is a suitable system for studying parasitic nematode genes
that may be involved in drug resistance.
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Introduction
Infections with parasitic nematodes are a major problem in
animal health, and for human health in less-developed parts of the
world [1]. Currently, the only effective means of control is by
treatment with chemical anthelmintics [2]. One of the major
classes of anthelmintic is the macrocyclic lactones (MLs), which
include ivermectin and moxidectin, and these have been widely
used in agriculture [3] and, in the case of ivermectin, human
medicine [4,5]. However, some species of parasite, especially those
infecting small ruminants, have become resistant to the MLs, and
this is threatening sustainable worm control in those animals [6,7].
There have also been suggestions of the emergence of ML
resistance in human parasites [8,9], so there is an urgent need to
understand the genetic basis of this resistance. Unfortunately,
many informative genetic experiments in parasitic nematodes are
extremely difficult, so for some time there has been an interest in
exploiting the free-living species, Caenorhabditis elegans, for such
studies, taking advantage of the powerful genetic and behavioural
tools that can be applied to this organism[10]. Haemonchus contortus
is an economically important parasite of small ruminants which
has developed widespread resistance to anthelmintic drugs,
including the MLs [6]. The major targets of the MLs are the
glutamate-gated chloride channel (GluCl) receptors; activation or
potentiation of these channels in GI nematodes by the drugs
produces paralysis and inhibition of feeding [11], and in filarial
nematodes inhibits protein secretion [12]. An improved under-
standing of the contribution of GluCl receptors to anthelmintic
actions and resistance would aid in developing new pharmaco-
logical strategies against parasitic nematodes.
Investigation of the behavioural and drug target roles of
individual GluCl subunits in parasitic nematodes is hampered by
several limitations. The requirement for a host to complete the
lifecycle of the parasite is a major obstacle in producing mutant
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strains of parasitic nematode required for a detailed analysis of
GluCl subunit function. Transgenesis of parasitic nematodes is
possible [13,14], and some parasitic nematodes are more
amenable to this strategy than others. For example Strongyloides
stercoralis has been successfully transformed [15,16,17] although
this parasite is unusual in that it has free-living generations which
alternate with parasitic generations. H. contortus has not been
successfully used in studies of transgenesis so far, although RNAi
may be useful in the future for studying genes in H. contortus by
gene knockdown [18,19]. Due to the powerful genetic techniques
available when working with the free living model organism C.
elegans, our aim was to exploit C. elegans for the study of H. contortus
GluCl subunit function in vivo. Successful expression of subunits
from the parasite in C. elegans would enable us to interrogate the
function of particular GluCl subunits.
Several other investigators have looked at the ability of parasite
gene products to express successfully in C. elegans. Gillan et al.,
studying hsp-90, found that the H. contortus orthologue produced
only a partial rescue of the C. elegans mutation, whereas the
orthologue from Brugia pahangi, a more distantly related parasite,
failed to produce any rescue [20]. Other H. contortus genes that
have been successfully expressed in C. elegans include cathepsin L
[21], the transcription factor elt-2 [22] and b-tubulin, where Kwa
et al [23] showed that polymorphisms associated with benzimid-
azole resistance would cause the transgenic C. elegans to become
drug resistant. Genes from other parasites have also been
expressed; Kampkotter et al [24] showed that a glutathione-S-
transferase from Onchocerca volvulus would make C. elegans more
resistant to oxidative stress and Massey et al. [25] showed that a
forkhead transcription factor from Strongyloides stercoralis would
rescue daf-16 associated defects. In contrast, Crook et al. [26]
found that a putative daf-7 orthologue from Parastrongyloides
trichosuri (Ptr-daf-7 – genetic nomenclature as proposed by Beech
et al. [27]) did not complement C. elegans daf-7 mutants. Very
recently, Welz et al [28] showed that expression of the Ancylostoma
caninum SLO-1 channel could completely rescue the emodepside
sensitivity of a slo-1 null mutant of C. elegans, demonstrating the
utility of the free-living nematode for the expression of parasite
drug targets.
Studying genes that may be involved in macrocyclic lactone
action and resistance in this manner has the potential to be
challenging as there are multiple genes encoding ivermectin-
sensitive GluCl subunits in nematodes. C. elegans has six GluCl
genes, with at least two of these being alternatively spliced [29]; in
H. contortus there are also six known GluCl genes coding for at least
seven subunits, however the composition of the two gene families is
not the same (Table 1). The gene family from C. elegans contains
two genes, Cel-glc-1 and Cel-avr-15, for which structural ortholo-
gues have not been described in H. contortus and the parasite has
two genes, Hco-glc-5 and Hco-glc-6, which are not present in C.
elegans [27]. The subunits are, by analogy with nicotinic and
GABAA receptors, assumed to combine to form pentameric
receptors, however the subunit composition and stoichiometry of
the functional receptors in vivo in either species is unknown. Many,
but not all, GluCl subunits form ivermectin-sensitive channels
when expressed in vitro (Table 1). An important similarity between
the two nematodes is the presence of the avr-14 gene, which has
structural orthologues not only in these two species, but in all
nematode genomes examined so far [30,31,32]. This gene is
alternatively spliced to produce AVR-14A and AVR-14B subunits;
the alternatively spliced subunits share 81% and 82% amino acid
sequence similarity between each other in H. contortus and C. elegans
respectively [30]. The AVR-14B subunits have 87% amino acid
sequence identity between the two worm species, while for AVR-
14A the identity is 88%. The AVR-14 subunits share a common
N-terminal ligand-binding domain but diverge thereafter in the
sequence that forms the ion channel and intracellular domain.
Previously we have shown that expression of Hco-AVR-14A and –
AVR-14B in avr-14 mutant C. elegans can rescue the behavioural
abnormality, increased reversal frequency, associated with the
mutation [33]. However, mutations in avr-14 alone are not
sufficient to make C. elegans resistant to ivermectin [34], so it was
not possible to test the effects of the parasite subunits on drug
resistance in those studies.
In the experiments reported here we make use of the triple
GluCl mutant C. elegans line DA1316, which has 4,000 fold
resistance to ivermectin in a growth assay compared to wild-type
[34]. The three GluCl genes with mutations in DA1316 are avr-14,
avr-15 and glc-1, with the mutations in the former two genes
producing null-function subunits for both splice variants. DA1316
was selected as the background mutant to test the hypothesis that
GluCl subunits from H. contortus could rescue the ivermectin
sensitivity of mutant C. elegans. In addition, we wished to examine
whether other members of the GluCl gene family could also rescue
an avr-14 defect; whether only orthologous genes were capable of
accurately rescuing the C. elegans phenotype or whether paralogous
genes were also capable of restoring drug sensitivity. Overall, these
experiments test the usefulness of C. elegans as an expression system
for studying drug resistance and other genes from a parasitic
species.
Results
avr-14 Expression Pattern
The expression pattern of wild type C. elegans transformed with a
transcriptional reporter construct incorporating a 1,700 bp avr-14
promoter fragment showed GFP expression in the nerve ring,
ventral nerve cord and sensory neurones in the body (Fig. 1). This
construct accurately reproduced the pattern shown previously
using a similar avr-14 promoter [34]. Expression was also clear in
the amphidial neurones of the head and the phasmid neurones of
the tail (Fig. 1).
Rescue of ivermectin sensitivity of DA1316 with C.
elegans and H. contortus avr-14 cDNAs
The movement of the triple GluCl mutant strain, DA1316, was
not affected by exposure to 1 mM ivermectin after 1 hour, in
contrast to the total paralysis of 100% of wild type C. elegans that
was observed under the same conditions (Fig. 2). In order to
confirm that this resistance could be reversed by expression of one
of the genes mutated in DA1316, avr-14, we transformed DA1316
with three subunit cDNAs (Cel-avr-14a, Cel-avr-14b or Hco-avr-14b)
under the control of the avr-14 promoter. Transformation with any
of these cDNAs resulted in rescue of ivermectin sensitivity to
varying degrees (Fig. 2A and B), with statistically significantly
greater numbers of worms paralysed by exposure to 1 mM
ivermectin in all the transgenic worm lines tested, compared to
the parent DA1316. In particular, the avr-14b cDNA of both
nematode species resulted in a robust rescue, with at least 79% of
the tested worms becoming immotile in the presence of ivermectin.
This result was obtained with two different lines expressing the C.
elegans subunit, where 9363.4% and 9565.0% of the worms were
paralysed, and four lines expressing the H. contortus subunit, where
the proportion that were paralysed varied from 79612.1% to
9264.5%. The results with the lines transformed with both the C.
elegans and H. contortus avr-14b cDNAs were similar to both wild-
type worms and to DA1370, a double mutant strain (avr-15; glc-1)
that is only weakly resistant to ivermectin [34]. The three lines
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containing Cel-avr-14a cDNA in DA1316 showed different levels of
ivermectin sensitivity, from 3368.6% of line 2 paralysed to
78611.8% of line 1; the differences between avr-14A lines 2 & 3,
and the avr-14B lines were significant (p =,0.01).
In an attempt to obtain more quantitative data on the level of
drug sensitivity of the transgenic lines, we carried out thrashing
assays in varying concentrations of ivermectin, and compared the
results obtained by counting manually with those obtained with an
automated system [35]. In summary, the thrashing rates of the
transformed worms were similar to those of wild type, showing a
greater sensitivity to ivermectin than the untransformed triple
mutant, DA1316. There was no significant difference between the
thrashing rates (75616 to 9564 thrashes/min) of any of the lines
when placed in 0.1% (v/v) DMSO as a vehicle only control. The
dose-response curve of DA1316 indicated that these worms
become susceptible to the paralytic effects of ivermectin at
concentrations above 10 mM (Fig. 2C). Even at 10 mM ivermectin,
C. elegans with mutations in the three GluCl subunit genes reduced
their thrashing rate by only 50%. In contrast, the transformation
of DA1316 with avr-14b cDNA from either C. elegans or H. contortus
resulted in an increase in the sensitivity of these worms to
ivermectin to such an extent that they had a thrashing rate of only
261 and 262 thrashes/min respectively at 10 mM drug, and their
thrashing rate was reduced by more than 50% at 1 mM
ivermectin. The results from transgenic worms expressing Cel-
AVR-14A were more variable, with two out of three lines
retaining some activity in 1 mM ivermectin (Fig 2A).
The automated thrashing assay produced very similar results to
those obtained by the more laborious manual thrashing assay, with
rescue of the ivermectin sensitivity observed for DA1316
expressing all of the avr-14 cDNAs (Fig. 2D). The nature of the
assay allowed us to measure more ivermectin concentrations, and
also more C. elegans strains simultaneously than was possible with
the manual thrashing assay. Importantly, very similar thrashing
rates and dose-response curves were produced using the two
different methods.
Chronic Ivermectin Sensitivity Assay
The previous assays both measured the sensitivity of the worms
to an acute exposure to ivermectin. However in vivo drug exposure
would be much longer-term, with potential effects at lower
concentrations than were used in the motility assays. The chronic
ivermectin sensitivity assay, or growth assay, involved placing eggs
onto nematode growth medium containing different concentra-
tions of ivermectin and is a useful measure of the combined effects
of ivermectin on foraging (locomotion) and pharyngeal pumping
activity in different lines of C. elegans. Control plates containing
0.1% (v/v) DMSO were also set up during each experiment to
account for any non-ivermectin related effects. The triple mutant
line was resistant to ivermectin throughout the concentration
range used, whereas no wild type adults were observed at
concentrations above 1 nM ivermectin (Fig 3A). All the avr-14
cDNAs conferred ivermectin sensitivity onto DA1316, and no
adults were observed at concentrations of 3nM and above.
Behavioural Assay
Our previous study had indicated that mutations in GluCl
subunits affected the reversal frequency of C. elegans, with avr-14
mutants reversing more frequently than wild-type, and also that
expression of the H. contortus AVR-14B could rescue this
abnormality in an avr-14 mutant strain [33]; indeed, expression
of H. contortus AVR-14B caused the worms to reverse less
frequently than wild-type. However, the experiments in that study
had not included DA1316, which has an additional mutation in
Table 1. The glutamate-gated chloride channel gene families of C. elegans and H. contortus.
C. elegans H. contortus Comments
avr-14 avr-14 Alternatively spliced to form two subunits [30,31]. AVR-14B forms glutamate- and ivermectin-gated channels [34,43].
avr-15 Alternatively spliced to form two subunits. Forms glutamate- and –ivermectin sensitive channels [48,49].
glc-1 Forms ivermectin-sensitive channels when expressed alone; these are gated by glutamate when co-expressed with GLC-2 [36].
glc-2 glc-2 Does not form ivermectin-sensitive channels when expressed alone. Cel-GLC-2 forms glutamate-gated channels; these are
sensitive to ivermectin when co-expressed with GLC-1 [36].
glc-3 glc-3 Cel-GLC-3 forms glutamate- and ivermectin-gated channels [50]. Hco-glc-3 has only recently been identified.
glc-4 glc-4 No functional data. Sequence is somewhat divergent from other GluCl genes [51].
glc-5 Forms ivermectin- and glutamate-gated chloride channels [52].
glc-6 No functional data.
doi:10.1371/journal.pone.0022390.t001
Figure 1. Expression pattern of GFP under the control of the
avr-14 promoter. The avr-14 promoter fragment used was a section
1.7 kb upstream of the initiation codon. A) Whole adult wild type C.
elegans transformed with a Cel-avr-14::gfp construct. vnc = ventral
nerve cord; nr = nerve ring. B) Head section. an = amphidial neurones;
vnc = ventral nerve cord. C) Body section between vulva and tail. pds
= posterior deirid sensilla neurone cell bodies; vnc = ventral nerve
cord. D) Tail section. phn = PHA, PHB and PHC neurone cell bodies. vnc
= ventral nerve cord.
doi:10.1371/journal.pone.0022390.g001
Expression of Parasite GluCl in C. elegans
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22390
glc-1 [34], so we tested whether DA1316 also reversed more
frequently, and to identify whether any altered number of reversals
could again be rescued using Hco-avr-14b or Cel-avr-14b cDNA
(Fig. 3B). The reversal frequency of DA1316 was not significantly
elevated compared with wild-type, indicating that loss of a
functional glc-1 offset the increase caused by mutations in avr-14
and avr-15 [33]. DA1370, the double mutant (avr-15;glc-1) also
reversed at the same frequency as the wild-type worms, adding
additional support for this suggestion. The expression of Cel-AVR-
14B had no effect on the reversal frequency of DA1316, but
transforming the triple mutant with Hco-avr-14b cDNA produced
worms with a severely reduced ability to reverse at normal
frequencies.
Rescue by other C. elegans and H. contortus GluCl
subunits
The GluCl are pentameric channels, there are multiple GluCl
subunit genes in both C. elegans and H. contortus and the subunit
composition of the native channels is not known. In vitro, Cel-
GLC-1 and -GLC-2 can co-assemble to form functional channels
[36]; in vivo, Cel-glc-2 is expressed only in the pharynx [37], where
Cel-avr-15 is also expressed [38], and the expression pattern of Cel-
glc-1 has not yet been determined. In H. contortus, the expression
patterns of Hco-AVR-14 and Hco-GLC-5 overlap [39], though
whether the two subunits co-assemble is not known. If, in vivo,
AVR-14 subunits co-assemble with others to form ivermectin-
sensitive heteromeric channels, this might mean that expression of
non-orthologous GluCl genes would not rescue the ivermectin-
resistance phenotype effectively, perhaps limiting the usefulness of
this approach for studying genes from other species. We therefore
transfected DA1316 with cDNAs encoding other ivermectin-
sensitive subunits from C. elegans (glc-1, glc-3, avr-15) and H. contortus
(Hco-glc-5). We also used cDNA encoding an ivermectin-insensitive
subunit, Hco-GLC-2 [40] and an uncharacterised subunit, Hco-
GLC-6 [27], from H. contortus. All of the cDNAs were sub-cloned
behind the same avr-14 promoter used previously. The results,
Figure 2. Motility assays showing rescue of ivermectin sensitivity by avr-14 cDNAs in the resistant DA1316 mutant. N=3. Asterisks
indicate a significant difference (p =,0.05) between the transgenic lines and the parent DA1316 triple mutant (avr-14; avr-15; glc-1). A) Ivermectin
sensitivity, assessed by counting the number of stationary worms after exposure to 1 mM ivermectin for 1 hr, of DA1316 transformed with either Cel-
avr-14a (3 lines) or Cel-avr-14b (2 lines) cDNA. B) Ivermectin sensitivity of DA1316 transformed with Hco-avr-14b cDNA (4 lines), assessed as in panel A).
For panels A & B, data are presented as mean 6 SEM and a one-way ANOVA and Tukey’s post-hoc test were performed on the two data sets
separately using Minitab. Wild-type N2 worms and the DA1370 double mutant (avr-15; glc-1) are included for comparison. C) The effect of ivermectin
on nematode swimming measured as ‘‘thrashes’’ per minute (as % of vehicle control) for wild type and transgenic C. elegans lines. Hco-avr-14b in
DA1316 line 2 and Cel-avr-14b in DA1316 line 1 were chosen as representative lines from the motility assay for use in the thrashing assays. The
experiment was repeated 3 times, with 8 worms per strain per concentration. D) An automated thrashing assay on the same lines as in panel C. The
experiment was repeated between 1 and 4 times for each data point. Curves were fitted using the variable slope sigmoidal equation in GraphPad
Prism (San Diego). The data are presented as mean 6 SEM with N= 3. Symbols as in panel C).
doi:10.1371/journal.pone.0022390.g002
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shown in Figure 4, show that of the C. elegans subunits, all three
lines expressing Cel-AVR-15 were almost completely sensitive to
1 mM ivermectin, whereas those expressing Cel-GLC-3 or Cel-
GLC-1 were only partially sensitive to this concentration of the
drug. Expression of the H. contortus GLC-5 subunit also caused a
partial rescue of the sensitivity to 1 mM ivermectin, and complete
sensitivity to 10 mM, whereas expression of Hco-GLC-2 did not
produce any significant changes to DA1316, which is consistent
with the insensitivity of GLC-2 channels to ivermectin [36,40].
The uncharacterised Hco-GLC-6 subunit produced an almost
complete rescue of drug sensitivity, indicating that it either
produces ivermectin-sensitive channels, or can combine with pre-
existing subunits to form such channels.
Discussion
The study of polymorphisms and mutations potentially involved
in anthelmintic resistance of parasitic nematodes is complicated by
the difficulty of carrying genetic experiments on these organisms.
Though in vitro studies are useful, especially in the case of those
drugs which affect ion channels, in vivo confirmation that a
particular sequence change does alter the organism’s response to
drug application is always desirable. C. elegans has been used as an
expression system for many parasite genes, including those
involved in resistance to the benzimidazole anthelmintics [23],
and so it seemed an obvious question to ask if it is a suitable system
for studying genes which encode targets of the MLs, and are thus
candidate resistance genes [41]. The MLs act on glutamate-gated
channels, either directly activating them or potentiating their
response to glutamate [11]. The GluCls are expressed widely in
the nematode nervous system, and are encoded by a small gene
family; this family differs in size and composition between species,
with some genes, such as avr-14, being widely conserved and others
seeming to be present in much fewer species [27,29,32]. The
presence of multiple potential targets in parasitic species, some of
which do not have orthologues in C. elegans, as is the case for H.
contortus, raises some interesting problems, especially if they are
required to assemble with other subunits to form heteromeric
receptors in order to be fully functional.
We addressed some of these issues by expressing multiple GluCl
subunits from both C. elegans and H. contortus in a C. elegans strain
(DA1316) that is very resistant to ivermectin, and by testing the
sensitivity of the transgenic worms to the drug. DA1316 is a triple
mutant strain (avr-14, avr-15, glc-1) but the double mutant (avr-15,
glc-1) has a very low-level of resistance [34], so that even partial
rescue of the avr-14 mutation would produce a clear shift in
response to the drug. A rescue of ivermectin sensitivity implies that
the recombinant subunit forms, either by itself or by assembling
with other endogenous polypeptides, a functional drug-sensitive
channel. We chose H. contortus as the source of the parasite cDNAs
for this study because it is a member of clade V like C. elegans, and
is therefore not too phylogenetically distant [42], and because it
encodes a number of ivermectin-sensitive GluCl subunits, not all
of which have orthologues in the C. elegans genome (Table 1). The
expression of GFP under the control of the avr-14 promoter
fragment showed that any recombinant subunits would be
expressed in the same cells as the C. elegans avr-14 gene products
and, as predicted by our previous results [33], expression of both
Cel-AVR-14B and Hco-AVR-14B restored the worms to almost
complete drug sensitivity. A caveat to that statement is that we do
not know which of the splice variants, AVR-14A or AVR-14B, are
normally expressed in these cells, nor should it be assumed that the
expression of this gene in parasitic species would be the same as in
C. elegans. Indeed, for both H. contortus and Brugia malayi, there is
evidence that it is not [12,39]. Despite this, expression of Hco-
AVR-14B not only rescued a behavioural defect associated with
avr-14, an increased reversal frequency, but caused the worms to
reverse less frequently than wild-type, as previously reported [33].
This unexpected result may be related to the much greater
potency of L-glutamate on the Hco-AVR-14B receptor
(EC50 = 27.6 mM) than on Cel-AVR-14B (EC50 = 2.2 mM) that
we observed in vitro [43]. If one of the roles of AVR-14 is to
suppress the initiation of reversals [33], then activation of Hco-
AVR-14B by lower concentrations of glutamate may cause this
Figure 3. Development and behavioural assays demonstrating rescue of the avr-14 phenotypes. A). The number of eggs that developed
to adulthood on different concentrations of ivermectin. There is rescue of ivermectin sensitivity by Cel-avr-14a, Cel-avr-14b and Hco-avr-14b cDNA in
the resistant DA1316 mutant. Data are presented as mean6 SEM. B) The DA1316 triple mutant transformed with Hco-avr-14b cDNA carried out fewer
reversals per minute than the other lines. Reversals per minute were counted to compare WT, DA1316 (glc-1; avr-14; avr-15) and DA1316 containing
either Cel-avr-14b or Hco-avr-14b cDNA behind the Cel-avr-14 promoter. The double mutant, DA1370 (avr-15; glc-1), which has mutations in glc-1 and
avr-15 was also used as a comparison. * Indicates that the reversals of the line containing the cDNA from the parasite were significantly reduced
compared to DA1316, WT and DA1316 containing Cel-avr-14b cDNA. No difference was detected between the reversal frequencies of WT, DA1316,
DA1370 or Cel-avr-14b in DA1316, using a one-way ANOVA (Minitab). Data are presented as mean 6 SEM with N=10 worms for each line.
doi:10.1371/journal.pone.0022390.g003
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suppression to last longer than in wild-type worms. The
observation that DA1316 reversed with a similar frequency to
wild-type is presumably due to the mutation in glc-1, which must
be able to suppress the increase in reversal frequency caused by the
avr-14 and avr-15 mutations. We have previously shown that not
all mutation in GluCl genes cause an increase in reversal
frequency; a deletion in glc-3 causes a marked decrease in reversal
frequency [33]. This is supported by the result with DA1370,
which carries mutations in avr-15 and glc-1. This strain showed no
abnormality in reversal frequency (Figure 3B), unlike avr-15 single
mutants [33] which strongly suggests that the glc-1 allele is
suppressing this effect of the avr-15 mutation The ivermectin
resistance of the transgenic lines was measured in a variety of
assays, and all gave essentially the same result, that the resistance
of DA1316, whether to acute or chronic exposure, was reversed by
expression of the AVR-14 subunits (Figures 2 & 3).
Mutations in the GluCl of ivermectin-resistant isolates of
parasitic nematodes have been observed, in particular in Cooperia
oncophora [44], and these mutations affect the sensitivity of the
channels to ivermectin in vitro [43,44]. In addition, mutations in
the have been made in both the mammalian glycine receptor and
the nematode GluCl that reduce or abolish the effect of ivermectin
[45]. These amino-acid residues are found in M3 and contribute
to the recently described binding site of ivermectin in the
membrane domain of the GluCl [46]. It would be interesting to
test such mutants of AVR-14B in transgenic C. elegans, to confirm
that they do not rescue drug sensitivity and to examine whether
the decreased reversal frequency shown in Figure 3B is still
observed, and correlates with the in vitro potency of glutamate at
these receptors.
These experiments showed that orthologous gene products from
a parasitic nematode were functionally expressed in C. elegans, so
we then looked at some paralogous gene products from both
species. Figure 4 shows that those subunits that formed ivermectin-
sensitive subunits in vitro also rescued the drug resistance
phenotype, at least to some extent, though there were some
quantitative and qualitative differences between some of the lines
expressing paralogues and orthologues. Such a rescue could have
Figure 4. Other ivermectin-sensitive subunits from both C. elegans and H. contortus rescue the drug resistance of DA1316. A) Paralysis
assay on lines transformed with cDNA expressing other C. elegans GluCl subunits. The proportion of worms that were paralysed by immersion in 1 mM
ivermectin for 1 hr is shown. B) Thrashing assay of the lines from panel A. The number of thrashes/minute of the worms following a 1 hr exposure to
1 mM ivermectin is indicated. C) Paralysis assay on worms transformed with cDNAs expressing H. contortus GluCl subunits. D) Thrashing assay at three
different concentrations of ivermectin, carried out on some of the lines shown in C). For panels A, B & C, * = statistically significant difference from
DA1316 (p#0.05).
doi:10.1371/journal.pone.0022390.g004
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come about in one of two ways; either the paralogous subunits were
able to assemble with the normal partners of the endogenous AVR-
14 subunits to form a functional GluCl, or they formed novel
ivermectin-sensitive channels that silenced avr-14 expressing
neurones on exposure to the drug. The ivermectin insensitive
subunit, Hco-GLC-2 [40], was not able to rescue ivermectin
sensitivity but interestingly Hco-GLC-6 [27], which has not yet
been studied by in vitro expression in Xenopus oocytes or in cell
culture, was able to rescue the avr-14 defect, suggesting that this
subunit also contributes to an ivermectin-sensitive channel.
Taken together, the data show that C. elegans is a good system for
the expression of parasite ion channels that act as drug targets, and
is likely to be a reliable way of assessing the contributions of
sequence polymorphisms within these subunits to a drug resistance
phenotype. If this is true for ivermectin and the GluCl, then similar
assays should be useful for the many drugs that act at nicotinic
acetylcholine receptors, especially those that cause paralysis. The
use of the model organism may help to overcome the formidable
barriers to carrying out genetic experimentation on parasites.
Methods
C. elegans wild-type and mutant strains were cultured according
to standard techniques, and were maintained at 19uC on
nematode growth medium (NGM) agar plates seeded with OP50
bacteria.
Transformation of C. elegans
The C. elegans and H. contortus GluCl cDNA fragments were
cloned behind a Cel-avr-14 promoter fragment, as described
previously [33]. The avr-14 promoter was a 1700 bp fragment
from immediately upstream of the avr-14 translational start site. To
test the expression pattern of this promoter fragment, a
transcriptional GFP reporter construct was made by cloning the
avr-14 promoter fragment into a vector containing GFP (pPD95.75
Fire Vector Kit 1995, Addgene plasmid 1494) [47]. The reporter
construct was used to transform N2 (wild type) C. elegans and the
expression pattern examined (MZ16 F Fluorescence Stereomicro-
scope, Leica) (Fig. 1). The sequence of the Hco-glc-6 cDNA is
deposited under Accession number EU006789.
Transformation of C. elegans was carried out using DNA-coated
gold particle bombardment (Bio-Rad PDS-1000 with hepta
adaptor for increased transformation efficiency). For the rescue
experiments, the DA1316 strain (avr-14; avr-15; glc-1 triple mutant:
[34]) was bombarded using a total of approximately 3 mg of DNA.
The co-transformation marker (myo-3::gfp, pPD118.20 Fire Lab
Vector Kit 1997, Addgene plasmid 1592) and the test DNA were
on separate plasmids, which were linearized by digestion with ApaI
or KpnI in standard buffers (NEB) in a total reaction volume of
50 ml for each plasmid. The DNA solutions were then mixed
together and precipitated onto gold particles. Transformation was
carried out under 1500 psi of helium gas pressure and a chamber
vacuum of 21 mmHg. Subsequently, transformants expressing
GFP in the body wall muscle were picked and successful lines were
maintained. The presence of the test DNA was verified for each
line using single worm PCR, with primers either specific to the
start and end of the cDNA sequence (for H. contortus cDNA) or by
designing primers that spanned exon-exon junctions (for C. elegans
cDNA). In practise, 100% of lines expressing the myo-3::gfp
construct contained the test DNA. At least two separate lines were
produced for each GluCl cDNA tested. A control line was
produced by transforming DA1316 with the myo-3::gfp construct
only, and this line is used in place of untransformed DA1316
throughout the rest of the assays.
Acute ivermectin sensitivity assays
Motility assay. A survey of the ivermectin sensitivity of the
multiple lines was carried out for all worm strains produced.
Ten individual worms were picked from each line/strain into
96-well plates with wells containing 50 ml M9 salts, two wells per
line. 50 ml of 2 mM ivermectin solution was added to each well
to produce a final concentration of 1 mM. The worms were left
at 19uC for 1 h, after which time the number of stationary
worms in each well was counted. The experiments were carried
out in triplicate and using the data from this assay, one
representative line containing each construct was chosen for use
in the thrashing assay, chronic ivermectin sensitivity assay and
behavioural assay.
Thrashing assay. Thrashing assays were carried out at
different concentrations of ivermectin to characterise the drug
sensitivity of the avr-14B transgenic lines more fully. The thrashing
assay was carried out using two different methods: manual
thrashing assay and automated thrashing assay. The two
methods were used to verify the measurements thoroughly.
For the manual thrashing assay, individual young adult C.
elegans were placed in 100 ml of ivermectin solution (made up in
M9 buffer) in a 96-well microtitre plate. After 30 minutes in
the drug at 19uC, the number of thrashes (bends of the body
from one side to the other and back) were counted for 1
minute. A preliminary time-course investigation (data not
shown) indicated that 30 minutes would be the appropriate
duration in the drug at the ivermectin concentrations used
(0.03 to 8.75 mg/ml). The experiment was carried out for 8
worms per strain, per ivermectin concentration and was
repeated on two further days. The GluCl-transformed lines
were chosen as representative lines, after inspection of the
motility assay data. One thrash was counted as a movement of
the head to one side e.g. a thrash was counted every time the
head of the worm moved to the left.
The automated thrashing assay was carried out as for manual
thrashing, except that the thrashing rates for all worms could be
measured simultaneously. Movies were taken of the whole 96-well
plate, and thrashing rates calculated for each well by the co-
variance method as described previously [35].
Chronic ivermectin sensitivity assay
NGM was made, allowed to cool, and spiked to contain a final
concentration of either 0.01% DMSO or ivermectin at 100 pM or
1, 3.2, 10, or 100 nM. The NGM was transferred to 12-well
plates, allowed to set and seeded with 50 ml OP50. After 2 days at
room temperature, egg preparations of the different C. elegans lines
were made, and eggs were transferred onto the ivermectin/
DMSO plates. The number of adult worms in each well was
counted six days later. Three replicate wells per ivermectin/
DMSO concentration per worm strain were set-up, and the whole
experiment was repeated on two subsequent occasions.
Behavioural assay – reversal frequency
The frequency of reversals was as described by Cook et al [33].
Individual worms were picked onto an unseeded NGM plate (to
remove traces of bacteria), and then transferred to the measure-
ment NGM plate (also unseeded) where they were left to
acclimatise for 5 min. The number of reversals (initiations of
backward movement) in 5 min was counted.
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